...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Calcineurin Activity Assay Measurement by Liquid Chromatography–Tandem Mass Spectrometry in the Multiple Reaction Monitoring Mode
【24h】

Calcineurin Activity Assay Measurement by Liquid Chromatography–Tandem Mass Spectrometry in the Multiple Reaction Monitoring Mode

机译:多反应监测模式下液相色谱-串联质谱法测定钙调神经磷酸酶活性

获取原文

摘要

BACKGROUND: Blood concentrations of the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus are currently measured to monitor immunosuppression in transplant patients. The measurement of calcineurin (CN) phosphatase activity has been proposed as a complementary pharmacodynamic approach. However, determining CN activity with current methods is not practical. We developed a new method amenable to routine use.METHODS: Using liquid chromatography–multiple reaction monitoring mass spectrometry (LC-MRM-MS), we quantified CN activity by measuring the dephosphorylation of a synthetic phosphopeptide substrate. A stable isotope analog of the product peptide served as internal standard, and a novel inhibitor cocktail minimized dephosphorylation by other major serine/threonine phosphatases. The assay was used to determine CN activity in peripheral blood mononuclear cells (PBMCs) isolated from 20 CNI-treated kidney transplant patients and 9 healthy volunteers.RESULTS: Linearity was observed from 0.16 to 2.5 μmol/L of product peptide, with accuracy in the 15% tolerance range. Intraassay and interassay recoveries were 100.6 (9.6) and 100 (7.5), respectively. Michaelis–Menten kinetics for purified CN were K m = 10.7 (1.6) μmol/L, V max = 2.8 (0.3) μmol/min · mg, and for Jurkat lysate, K m = 182.2 (118.0) μmol/L, V max = 0.013 (0.006) μmol/min · mg. PBMC CN activity was successfully measured in a single tube with an inhibitor cocktail.CONCLUSIONS: Because LC-MRM-MS is commonly used in routine clinical dosage of drugs, this CN activity assay could be applied, with parallel blood drug concentration monitoring, to a large panel of patients to reevaluate the validity of PBMC CN activity monitoring.
机译:背景:目前正在测量钙调神经磷酸酶抑制剂(CNIs)环孢霉素和他克莫司的血药浓度,以监测移植患者的免疫抑制情况。钙调神经磷酸酶(CN)磷酸酶活性的测定已被提议作为一种补充药效学方法。然而,用当前方法确定CN活性是不实际的。我们开发了一种适合常规使用的新方法。方法:使用液相色谱-多反应监测质谱(LC-MRM-MS),我们通过测量合成磷酸肽底物的去磷酸化来定量CN活性。产物肽的稳定同位素类似物用作内标,新型抑制剂混合物将其他主要丝氨酸/苏氨酸磷酸酶的去磷酸化作用降至最低。该方法用于测定从20名经CNI治疗的肾移植患者和9名健康志愿者中分离出的外周血单个核细胞(PBMC)中的CN活性。结果:在0.16至2.5μmol/ L的产品肽中观察到线性,准确度为公差范围为15%。批内和批间回收率分别为100.6(9.6)和100(7.5)。纯化的CN的Michaelis–Menten动力学为K m = 10.7(1.6)μmol/ L,V max = 2.8(0.3)μmol/ min·mg,对于Jurkat裂解液,K m = 182.2(118.0)μmol/ L,V max = 0.013(0.006)μmol/ min·mg。结论:由于LC-MRM-MS通常用于常规的临床药物剂量,因此可在单管中与抑制剂混合物一起成功测量PBMC CN活性。大量患者重新评估PBMC CN活动监测的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号